NYSE:NVRO - Nevro Stock Price, Forecast & News

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) issued its quarterly earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.58) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.27. The medical equipment provider earned $100.16 million during the quarter, compared to analysts' expectations of $92.27 million. Nevro had a negative net margin of 25.94% and a negative return on equity of 46.35%. The firm's revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.37) EPS. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Nevro.

9 brokerages have issued 12 month target prices for Nevro's stock. Their forecasts range from $65.00 to $115.00. On average, they anticipate Nevro's stock price to reach $88.22 in the next year. This suggests that the stock has a possible downside of 20.2%. View Analyst Price Targets for Nevro.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

Media stories about NVRO stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a news impact score of -1.7 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Nevro.

Nevro saw a increase in short interest in October. As of October 15th, there was short interest totalling 3,880,000 shares, an increase of 25.6% from the September 15th total of 3,090,000 shares. Based on an average daily trading volume, of 400,900 shares, the days-to-cover ratio is currently 9.7 days. Approximately 13.1% of the company's stock are short sold. View Nevro's Current Options Chain.

Some companies that are related to Nevro include Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), NuVasive (NUVA), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Cantel Medical (CMD), Glaukos (GKOS), Inspire Medical Systems (INSP) and Irhythm Technologies (IRTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Celgene (CELG), AbbVie (ABBV), Adobe (ADBE), Gilead Sciences (GILD), Incyte (INCY), Lam Research (LRCX) and Starbucks (SBUX).

Nevro's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (2.31%), Redmile Group LLC (2.08%), Point72 Asset Management L.P. (0.72%), Pictet Asset Management Ltd. (0.65%), Massachusetts Financial Services Co. MA (0.58%) and Millennium Management LLC (0.21%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pictet Asset Management Ltd., Massachusetts Financial Services Co. MA, State Street Corp, SG Americas Securities LLC, Rice Hall James & Associates LLC, First Trust Advisors LP and Partner Investment Management L.P.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Point72 Asset Management L.P., Voloridge Investment Management LLC, California Public Employees Retirement System, Man Group plc, Lisanti Capital Growth LLC, Tamarack Advisers LP and Creative Planning. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $110.49.

Nevro has a market capitalization of $3.43 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

The official website for Nevro is http://www.nevro.com/.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]